Snapshot: 2015 Medical Device Quality-Related Warning Letters
This article was originally published in The Gray Sheet
Executive Summary
A "Gray Sheet" analysis has discovered that the industry racked up its fewest number of FDA quality-related warning letters in nearly a decade. The agency released 74 warning letters to its website in calendar year 2015 that included at least one quality system violation. Other findings: letters to foreign firms is down; CAPA is the most-oft cited violation; and close-out letters hit a new peak. And check out our infographic, which includes a listing of where non-US letters went last year and a breakdown of other data.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.